Masimo
Prezzo: 179.95Società e modello di business
Masimo Corporation specializes in non-invasive monitoring technologies, primarily focusing on innovative medical devices that measure blood oxygen levels and other vital signs. Its core products include pulse oximeters, non-invasive hemoglobin monitors, and advanced monitoring solutions for hospitals and home care. Major business segments encompass hospital and home healthcare markets, with revenue primarily derived from product sales and recurring service contracts.
Profilo di investimento
The investment profile of Masimo is more aligned with balanced investors, given its focus on stable revenue generation through established products while navigating recent fluctuations in earnings. The absence of dividends and moderate growth potential suggests a cautious approach. Investors may consider a medium to long-term horizon for potential value realization, with liquidity reflecting a moderate level of trading activity.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 1.44 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -2.2% ↓
- Sorpresa EPS
- -22.0% peggio del previsto
- Volatilità 20g
- 0.2% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-05-26 02:50 | Vendi | Mantieni | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-18 04:09 | Mantieni | Vendi | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-08 15:26 | — | Mantieni | Weak fundamentals and mixed momentum signal caution. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-02-17 14:44 | Stifel Nicolaus | Rating peggiorato | — → 180 | 174.8004 |
| 2026-02-17 14:06 | Piper Sandler | Rating peggiorato | — → 180 | 174.78 |
| 2025-12-05 11:11 | Wells Fargo | Target alzato | 187 → 190 | 142.26 |
Ancora nulla